Suven Pharmaceuticals Limited
NSE: SUVENPHAR BSE: SUVENPHAR
NSE
1,202.20
34.10 (2.92%)
Prev Close
1168.1
Open Price
1168
Volume
330,131
Today Low / High
1157.9 / 1235
52 WK Low / High
598 / 1360
Range
1,142 - 1,262
BSE
1,207.05
39.20 (3.36%)
Prev Close
1167.85
Open Price
1167.85
Volume
3,056
Today Low / High
1157.15 / 1221
52 WK Low / High
597 / 1359
Range
1,147 - 1,267
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1202.2 (target range: 1,142 - 1,262), reflecting a change of 34.1 (2.91927%). On the BSE, it is listed at 1207.05 (target range: 1,147 - 1,267), showing a change of 39.2 (3.3566%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
1,168.00
2.93%
17 Apr
1,195.70
-2.31%
16 Apr
1,180.00
1.33%
15 Apr
1,155.20
2.56%
11 Apr
1,091.15
5.36%
09 Apr
1,080.00
-1.98%
08 Apr
1,101.90
-1.83%
07 Apr
940.00
12.05%
04 Apr
1,126.80
-3.44%
03 Apr
1,097.90
2.49%
02 Apr
1,097.70
-0.28%
01 Apr
1,137.00
-5.54%
28 Mar
1,093.45
5.26%
27 Mar
1,118.55
-0.75%
26 Mar
1,149.95
-3.20%
25 Mar
1,177.05
-2.19%
24 Mar
1,200.25
-2.06%
Suven Pharmaceuticals Limited Graph
Suven Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Suven Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,202.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,207.05 | 1,219.12 | 1,097.21 - 1,341.03 |
| 1,231.19 | 984.95 - 1,477.43 | ||
| 1,243.26 | 870.28 - 1,616.24 | ||
| Bearish Scenario | 1,207.05 | 1,194.98 | 1,075.48 - 1,314.48 |
| 1,182.91 | 946.33 - 1,419.49 | ||
| 1,170.84 | 819.59 - 1,522.09 |
Overview of Suven Pharmaceuticals Limited
ISIN
INE03QK01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
448,090
Market Cap
306,037,994,912
Last Dividend
0
Official Website
IPO Date
2020-03-09
DCF Diff
969.55
DCF
215
Financial Ratios Every Investor Needs
Stock Dividend of SUVENPHAR
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-09-09 | September 09, 22 | 5 | 5 | 2022-09-12 | 2022-10-02 | |
| 2022-05-13 | May 13, 22 | 1 | 1 | 2022-05-17 | 2022-06-08 | |
| 2022-02-15 | February 15, 22 | 2 | 2 | 2022-02-16 | 2022-03-10 | |
| 2021-08-13 | August 13, 21 | 1 | 1 | 2021-08-17 | 2021-09-30 | |
| 2021-02-17 | February 17, 21 | 1 | 1 | 2021-02-18 | 2021-03-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,051.35 Cr | 448.51 Cr | 602.84 Cr | 0.5734 | 0.00 Cr | 136.80 Cr | 460.76 Cr | 300.28 Cr | 11.80 | 467.72 Cr | 0.2856 |
| 2023-03-31 | 1,340.33 Cr | 585.42 Cr | 754.91 Cr | 0.5632 | 8.59 Cr | 18.90 Cr | 518.80 Cr | 411.29 Cr | 16.16 | 620.26 Cr | 0.3069 |
| 2022-03-31 | 1,289.80 Cr | 555.09 Cr | 734.72 Cr | 0.5696 | 10.35 Cr | 17.06 Cr | 541.63 Cr | 453.80 Cr | 17.83 | 674.01 Cr | 0.3518 |
| 2021-03-31 | 979.94 Cr | 420.20 Cr | 559.73 Cr | 0.5712 | 11.06 Cr | 16.05 Cr | 409.89 Cr | 362.34 Cr | 14.23 | 456.98 Cr | 0.3698 |
| 2020-03-31 | 806.94 Cr | 324.61 Cr | 482.34 Cr | 0.5977 | 14.13 Cr | 13.75 Cr | 358.38 Cr | 317.00 Cr | 6.23 | 400.13 Cr | 0.3928 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 47.23 Cr | 2,254.09 Cr | 203.42 Cr | 2,050.6635 Cr | 65.00 Cr | 17.77 Cr | 231.20 Cr | 786.78 Cr | 0.16 Cr | 0.00 Cr | 130.58 Cr | 106.8957 Cr |
| 2023-03-31 | 64.80 Cr | 1,965.74 Cr | 230.56 Cr | 1,735.1843 Cr | 70.34 Cr | 5.54 Cr | 312.81 Cr | 766.22 Cr | 25.57 Cr | 12.86 Cr | 117.10 Cr | 158.7658 Cr |
| 2022-03-31 | 44.56 Cr | 1,829.59 Cr | 302.41 Cr | 1,527.1803 Cr | 97.13 Cr | 52.56 Cr | 283.42 Cr | 561.95 Cr | 34.07 Cr | 37.33 Cr | 117.10 Cr | 210.2940 Cr |
| 2021-03-31 | 7.18 Cr | 1,474.47 Cr | 293.66 Cr | 1,180.8083 Cr | 143.04 Cr | 135.85 Cr | 201.08 Cr | 534.89 Cr | 27.85 Cr | 42.24 Cr | 361.19 Cr | 219.7480 Cr |
| 2020-03-31 | 11.70 Cr | 1,172.81 Cr | 328.05 Cr | 844.7627 Cr | 186.21 Cr | 174.51 Cr | 174.87 Cr | 455.65 Cr | 30.97 Cr | 8.31 Cr | 307.46 Cr | 200.3715 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 358.4831 Cr | -362.2532 Cr | -13.8023 Cr | 306.6962 Cr | -17.5716 Cr | 47.2312 Cr | -51.7869 Cr | 300.2805 Cr | -6.3512 Cr | 0.0000 Cr | 81.6149 Cr |
| 2023-03-31 | 450.9124 Cr | -194.8422 Cr | -235.8312 Cr | 165.1409 Cr | 20.2390 Cr | 64.8028 Cr | -285.7715 Cr | 559.7298 Cr | -26.3680 Cr | -203.6520 Cr | -29.3932 Cr |
| 2022-03-31 | 330.0002 Cr | -136.2069 Cr | -156.4121 Cr | 254.8135 Cr | 37.3816 Cr | 44.5638 Cr | -75.1867 Cr | 667.5898 Cr | -48.1944 Cr | -101.8260 Cr | -82.3369 Cr |
| 2021-03-31 | 383.4377 Cr | -311.3982 Cr | -76.5529 Cr | 272.5917 Cr | -4.5131 Cr | 7.1822 Cr | -110.8460 Cr | 467.6741 Cr | -42.4248 Cr | -25.4565 Cr | -26.2082 Cr |
| 2020-03-31 | 415.9501 Cr | -421.5255 Cr | 6.3677 Cr | 316.5355 Cr | 0.7924 Cr | 11.6953 Cr | -99.4146 Cr | 404.5118 Cr | 0.0000 Cr | -76.7229 Cr | -17.7739 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 307.15 Cr | 55.63 Cr | 251.52 Cr | 0.8189 | 97.35 Cr | 82.88 Cr | 3.26 | 133.41 Cr | 0.2698 |
| 2024-09-30 | 257.72 Cr | 52.06 Cr | 205.66 Cr | 0.7980 | 87.05 Cr | 81.98 Cr | 3.23 | 118.13 Cr | 0.3181 |
| 2024-06-30 | 230.69 Cr | 149.70 Cr | 80.99 Cr | 0.3511 | 94.39 Cr | 60.77 Cr | 2.39 | 79.93 Cr | 0.2634 |
| 2024-03-31 | 252.93 Cr | 176.89 Cr | 76.04 Cr | 0.3006 | 56.10 Cr | 53.37 Cr | 2.10 | 90.40 Cr | 0.2110 |
| 2023-12-31 | 219.82 Cr | 105.14 Cr | 114.68 Cr | 0.5217 | 66.74 Cr | 46.75 Cr | 1.84 | 79.49 Cr | 0.2127 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 36.82 Cr | 636.16 Cr | 672.98 Cr | 0.00 Cr | 215.48 Cr | 1,167.65 Cr | 892.76 Cr | 2,505.56 Cr | 477.14 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 821.13 Cr | 0.00 Cr | 0.00 Cr | 821.13 Cr | 0.00 Cr | 0.00 Cr | -2,050.66 Cr |
| 2024-03-31 | 50.50 Cr | 773.90 Cr | 824.39 Cr | 133.66 Cr | 231.20 Cr | 1,263.19 Cr | 786.78 Cr | 2,254.09 Cr | 203.42 Cr |
| 2023-12-31 | 753.50 Cr | 0.00 Cr | 753.50 Cr | 126.40 Cr | 253.20 Cr | 1,133.10 Cr | 782.70 Cr | 2,057.90 Cr | 76.50 Cr |
| 2023-09-30 | 57.58 Cr | 656.26 Cr | 713.84 Cr | 136.90 Cr | 271.46 Cr | 1,169.07 Cr | 761.25 Cr | 2,119.77 Cr | 184.37 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 60.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 53.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 46.75 Cr | 25.50 Cr | 0.00 Cr | 0.00 Cr | 25.50 Cr | 86.31 Cr | 60.81 Cr | 0.00 Cr | 25.50 Cr |
| 2023-09-30 | 79.56 Cr | 23.78 Cr | 0.00 Cr | 0.00 Cr | 23.78 Cr | 60.81 Cr | 37.02 Cr | 0.00 Cr | 23.78 Cr |
| 2023-06-30 | 120.59 Cr | 25.08 Cr | 0.00 Cr | 0.00 Cr | 25.08 Cr | 90.94 Cr | 65.86 Cr | 0.00 Cr | 25.08 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-25 | September 25, 20 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Chief Financial Officer
Mr. Himanshu Agarwal
Gender: male
Year Born: 1970
Executive Chairman
Mr. Vivek Sharma CPA
Gender: male
Year Born:
Chief Executive Officer
Dr. Sudhir Kumar Singh Ph.D.
Gender: Not Specified
Year Born: 1965
Head of Investor Relations
Ms. Cyndrella Carvalho
Gender: female
Year Born:
Chief Human Resources Officer
Mr. Gaurav Narain Bahadur
Gender: male
Year Born: 1970
Chief Commercial Officer
Dr. Declan Ryan Ph.D.
Gender: Not Specified
Year Born:
Company Secretary & Compliance Officer
Mr. Kundan Kumar Jha
Gender: male
Year Born:
MD & Director
Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju Ph.D.
Gender: Not Specified
Year Born:
Vice President of Corporate Affairs
Mr. Sunder Venkatraman
Gender: male
Year Born:
FAQs about Suven Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Dr. Sudhir Kumar Singh Ph.D..
What is the current market price of the stock?
The current price is ₹1,202.20.
What is the 52-week price range?
The range is ₹598-1360.
What is the market capitalization of the company?
The market capitalization is ₹30,603.80 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 109.55.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Suven Pharmaceuticals Limited (ISIN: INE03QK01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹30,603.80 crores and an average daily volume of 448,090 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.